Understanding end-of-life (EOL) and palliative care continues to grow. However, little attention has been paid to the experiences, preferences, and needs of older lesbian, gay, bisexual, transgender, and queer (LGBTQ) women. While some universal expectations or preferences at EOL exist, this population may not receive adequate or appropriate attention or reporting of unique EOL issues and experiences. Systematically search for and narratively review existing evidence concerning the expectations, preferences, and needs for palliative and EOL care of LGBTQ older women. A comprehensive literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles reporting needs, experiences, and perspectives of palliative care and EOL care among LGBTQ older women were evaluated. Articles published between 1996 and 2019 were retrieved from PsycINFO, MEDLINE, Cochrane Library, Academic Search Complete, AgeLine, CINHAL, PubMed, LGBT Life, SocINDEX, Women's Studies International, Joanna Briggs Institute, and Open Grey. A total of 16 articles were included. Articles described several concerns for the overall LGBTQ population; however, additional issues and experiences specific to older LGBTQ women were also identified, including vulnerability associated with isolation and poverty, women's social needs and support networks, and preferences for complementary care. There remains a need for further research with older LGBTQ women concerning palliative and EOL care, particularly around preparation for EOL and preferences for support. Inclusion of diverse populations in terms of sexual and gender identification are needed to fully understand how to provide appropriate and preferred support.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/jpm.2019.0639 | DOI Listing |
BMJ Open
January 2025
Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Introduction: Cardiovascular diseases (CVDs) present differently in women and men, influenced by host-microbiome interactions. The roles of sex hormones in CVD outcomes and gut microbiome in modifying these effects are poorly understood. The XCVD study examines gut microbiome mediation of sex hormone effects on CVD risk markers by observing transgender participants undergoing gender-affirming hormone therapy (GAHT), with findings expected to extrapolate to cisgender populations.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, San Diego, La Jolla, CA, USA.
Background: People identifying as sexual and gender minorities (SGM) may have higher risk for subjective cognitive decline and Alzheimer's disease, although the risk for Parkinson's disease dementia (PDD) has not been investigated. Male sex is associated with a higher risk for PDD, it is unclear whether SGM status impacts the risk.
Methods: Data were obtained from Fox Insight on April 5, 2023.
Background: Sexual-minority (e.g., lesbian, gay, bisexual [SM]) people may be at an increased risk of Alzheimer's disease or a related dementia (ADRD) from stress related to experiences of minoritization.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, NV, USA.
Background: Over 2.5 million LGBTQIA+ (lesbian, gay, bisexual, transgender, queer, intersex, asexual or another sexual and/or gender minority identity) adults in the U.S.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Background: The Institute on Methods and Protocols for Advancement of Clinical Trials in Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) (IMPACT-AD) is a novel multi-disciplinary training program funded by the National Institute on Aging (NIA) and the Alzheimer's Association for individuals seeking expertise in designing and conducting AD/ADRD trials. IMPACT-AD offers a Professionals Track for investigators in a variety of trial roles and a Fellowship Track for future AD/ADRD clinical trial principal investigators.
Method: To evaluate long-term training outcomes, alumni-scholars from the 2020-2022 courses (n = 109) were surveyed via REDCap in January 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!